Preclinical activity of ORIC-114, a highly selective, brain penetrant, irreversible kinase inhibitor, against atypical mutations in EGFR

被引：0
|
作者：
Junttila, M. R. [1 ]
Warne, R. [1 ]
Repellin, C. [1 ]
Sambucetti, L. [1 ]
Chang, J. [2 ]
Kim, S. [3 ]
Kim, H. Y. [3 ]
Shin, D. G. [3 ]
Park, D. H. [3 ]
Patel, R. [4 ]
Maneval, E. Chow [4 ]
Multani, P. S. [4 ]
Daemen, A. [5 ]
Friedman, L. [6 ]
机构：
[1] ORIC Pharmaceut Inc, Dept Biol, South San Francisco, CA USA
[2] ORIC Pharmaceut Inc, DMPK, South San Francisco, CA USA
[3] Voronoi Inc, Incheon, South Korea
[4] ORIC Pharmaceut Inc, Clin Dev, San Diego, CA USA
[5] ORIC Pharmaceut Inc, Translat Med Dept, South San Francisco, CA USA
[6] ORIC Pharmaceut Inc, Res Dept, South San Francisco, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.2378
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1345P
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Osimertinib, an irreversible next generation EGFR tyrosine kinase inhibitor, exerts anti-tumor activity in various preclinical NSCLC models harboring G719X mutant-EGFR
    Floch, Nicolas
    Bickerton, Sue
    Martin, Matthew J.
    Cross, Darren A.
    Smith, Paul D.
    CANCER RESEARCH, 2019, 79 (13)
  • [42] JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC
    Yu, M. R.
    Yun, M. R.
    Cho, H. B.
    Choi, H. B.
    Dong, G.
    Choi, S. J.
    Oh, S. Y.
    Lee, E. J.
    Duggirala, K. B.
    Lee, K.
    Lee, J. B.
    Lim, S. M. M.
    Hong, M. H.
    Jo, A.
    Seah, E.
    Kim, C.
    Cho, B. C.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S335 - S336
  • [43] OMO-1, a potent, highly selective, orally bioavailable, MET kinase inhibitor with a favorable preclinical toxicity profile, shows both monotherapy activity, against MET pathway-driven tumors, and EGFR TKI combination activity in acquired resistance models
    Libouban, Marion
    Jovcehva, Eleonora
    De lange, Desiree
    Janssens, Boudewijn
    Verhulst, Tinne
    Ogata, Souichi
    Wroblowski, Berthold
    Mevellec, Laurence
    Lu, Tianbao
    Clack, Glen
    Perera, Timothy
    CANCER RESEARCH, 2018, 78 (13)
  • [44] Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I
    Floc'h, Nicolas
    Lim, Sangbin
    Bickerton, Sue
    Ahmed, Afshan
    Orme, Jonathan
    Urosevic, Jelena
    Martin, Matthew J.
    Cross, Darren A. E.
    Cho, Byoung Chul
    Smith, Paul D.
    MOLECULAR CANCER THERAPEUTICS, 2020, 19 (11) : 2298 - 2307
  • [45] Preclinical characterization of LOX-22783, a highly potent, mutant-selective and brain-penetrant allosteric PI3Kα H1047R inhibitor
    Klippel, Anke
    Wang, Rui
    Puca, Loredana
    Faber, Andrew Lee
    Shen, Weihua
    Bhagwat, Shripad V.
    Karukurichi, Kannan
    Zhang, Feiyu Fred
    Perez, Carmen
    Rama, Ramon
    Ramos, Ana
    Zheng, Yi
    Bonday, Zahid
    Thomas, James
    Brooks, Harold B.
    Kindler, Lisa J.
    Bogner, Sarah M.
    Zolfaghari, Parisa
    Hicks, Mark, II
    Callies, Sophie
    Mattioni, Brian
    LeBrun, Laurie
    Durbin, Jim
    Anderson, Erin
    Mayne, Chris
    Kesicki, Edward
    Kolakowski, Gabrielle
    Andrews, Steven W.
    Brandhuber, Barbara J.
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [46] S49076, a kinase inhibitor of AXL, MET and FGFR with strong, selective preclinical activity against tumor cells with acquired resistance to EGFR inhibitors not carrying the T790M mutation
    Bertran-Alamillo, Jordi
    Molina, Miguel A.
    Valerie, Cattan
    Burbridge, Mike
    Teixido, Cristina
    Codony-Servat, Jordi
    Codony-Servat, Caries
    Rosell, Rafael
    CANCER RESEARCH, 2016, 76
  • [47] TAS-121, A Selective Mutant EGFR Inhibitor, Shows Activity Against Tumors Expressing Various EGFR Mutations Including T790M and Uncommon Mutations G719X
    Ito, Kimihiro
    Nishio, Makoto
    Kato, Masanori
    Murakami, Haruyasu
    Aoyagi, Yoshimi
    Ohe, Yuichiro
    Okayama, Takashige
    Hashimoto, Akihiro
    Ohsawa, Hirokazu
    Tanaka, Gotaro
    Nonoshita, Katsumasa
    Ito, Satoru
    Matsuo, Kenichi
    Miyadera, Kazutaka
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (05) : 920 - 928
  • [48] CLINICAL ACTIVITY OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 IN ADENOCARCINOMA OF THE LUNG WITH MUTATIONS IN THE KINASE DOMAIN OF HER2NEU
    De Greve, J.
    Decoster, L.
    De Mey, J.
    In 't Veld, P.
    Geers, C.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Teugels, E.
    Schallier, D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S90 - S91
  • [49] NUV-520 (NVL-520) is a brain-penetrant and highly selective ROS1 inhibitor with antitumor activity against the G2032R solvent front mutation.
    Pelish, Henry E.
    Tangpeerachaikul, Anupong
    Kohl, Nancy E.
    Porter, James R.
    Shair, Matthew D.
    Horan, Joshua C.
    CANCER RESEARCH, 2021, 81 (13)
  • [50] MTX-211, a dual and selective inhibitor of EGFR and PI3 kinase, shows promising activity in combination with MEK inhibition in preclinical models of pancreatic cancer
    Frankowski-McGregor, Christy
    Maust, Joel
    Ziemke, Elizabeth
    Mumby, Rachel
    Delaney, Amy
    Rehemtulla, Alnawaz
    Whitehead, Christopher
    Sebolt-Leopold, Judith S.
    CANCER RESEARCH, 2018, 78 (13)
12345